Anti-CD20 x Anti-CD22 Bispecific Antibody (IgG-IgG) (BSIG-049)

Anti-CD20 x Anti-CD22 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD20 and anti-CD22 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb is designed for the research of Lymphoma; Leukemia; Antoimmune disease; Immune dysfunction disease therapy.

Datasheet INQUIRY

Specifications

Targets

CD20 & CD22

Type

IgG-IgG

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Lymphoma; Leukemia; Antoimmune disease; Immune dysfunction disease

Targets

Target 1

CD20

Gene ID

931

UniProt ID

A0A024R507

Alternative Names

MS4A1; membrane-spanning 4-domains, subfamily A, member 1; B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16; B-lymphocyte antigen CD20; CD20 antigen; CD20 receptor; leukocyte surface antigen Leu-16; B-lymphocyte cell-surface antigen B1

Target 2

CD22

Gene ID

933

UniProt ID

P20273

Alternative Names

CD22; CD22 molecule; Cluster of differentiation 22; SIGLEC2; SIGLEC-2; B-cell receptor CD22; BL-CAM; CD22 antigen; T-cell surface antigen Leu-14; B-lymphocyte cell adhesion molecule; sialic acid binding Ig-like lectin 2; sialic acid-binding Ig-like lectin 2

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD20 x Anti-CD22 Bispecific Antibody (IgG-IgG) (BSIG-049). Click the button below to contact us or submit your feedback about this product.

Anti-CD20 x Anti-CD22 Bispecific Antibody (IgG-IgG) (CAT#: BSIG-049)

Specifications

Targets

Customer Reviews and Q&As